| Feb. 08, 2012 |
|
Merck Informs Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors |
|
| Feb. 08, 2012 |
|
Thomas E. Shenk To Retire From Merck's Board of Directors |
| Feb. 07, 2012 |
|
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar |
| Feb. 07, 2012 |
|
The NAMES Project Foundation and Merck Launch "Call My Name" National Tour AIDS Panel Making Workshop to Focus Attention on HIV/AIDS Crisis in African American Communities |
| Feb. 06, 2012 |
|
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia |
| Feb. 02, 2012 |
|
FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience |
|
| Feb. 02, 2012 |
|
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results |
| Jan. 26, 2012 |
|
Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2 |
| Jan. 25, 2012 |
|
New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease |
|
| Jan. 19, 2012 |
|
Merck Resolves Vioxx® Litigation in Canada |
| Jan. 09, 2012 |
|
Merck to Present at the 30th Annual J.P. Morgan Healthcare Conference |
| Jan. 06, 2012 |
|
TFDA Approves Merck’s ISENTRESS® (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy |
|
| Jan. 04, 2012 |
|
Merck to Present at Goldman Sachs 2012 Healthcare Event |
| Dec. 21, 2011 |
|
Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV |
|
| Dec. 15, 2011 |
|
Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection |
|
| Dec. 12, 2011 |
|
Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting |
|
| Dec. 06, 2011 |
|
Merck Establishes New MSD R&D Asia Headquarters |
| Dec. 05, 2011 |
|
Merck for Mothers and PATH Collaborate to Identify Innovations that Save Mothers' Lives |
| Nov. 22, 2011 |
|
Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney's Office for the District of Massachusetts Related to Vioxx® |
| Nov. 13, 2011 |
|
Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM |
| Nov. 11, 2011 |
|
Merck and Partners Make Progress In Long-Term Commitment to End River Blindness |
| Nov. 10, 2011 |
|
Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing |
| Nov. 10, 2011 |
|
Merck Executing on Strategy to Position Company for Long-Term Sustainable Growth |
| Nov. 10, 2011 |
|
Merck to Present at the 2011 Credit Suisse Healthcare Conference |
| Nov. 9, 2011 |
|
Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States - A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years |
|
| Nov. 5, 2011 |
|
Interim Data for Merck's VICTRELIS™ (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting |
|
| Nov. 2, 2011 |
|
FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN® (ezetimibe/simvastatin) for Use in Patients with Pre-Dialysis Chronic Kidney Disease |
|
|
| Oct. 31, 2011 |
|
Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report |
| Oct. 28, 2011 |
|
Merck Announces Third Quarter 2011 Financial Results |
| Oct. 26, 2011 |
|
New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males |
|
|
| Oct. 25, 2011 |
|
CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men |
|
| Oct. 24, 2011 |
|
Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) |
|
| Oct. 20, 2011 |
|
Interim Phase IIb Data for Merck's VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting |
|
| Oct. 13, 2011 |
|
Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1 |
|
| Oct. 07, 2011 |
|
FDA Approves Merck's JUVISYNC™ (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease |
|
| Oct. 06, 2011 |
|
Merck Announces Retirement of Chairman and Former CEO Richard T. Clark |
| Oct. 05, 2011 |
|
FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor |
| Oct. 04, 2011 |
|
Merck Adds New Medication Adherence Resources to Consumer Web Site |
| Oct. 03, 2011 |
|
Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium) |
| Sept. 30, 2011 |
|
Merck Announces New Data Analyses for VICTRELIS™ (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting |
|
| Sept. 30, 2011 |
|
Merck Publishes 2010 Global Corporate Responsibility Report |
| Sept. 30, 2011 |
|
Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28 |
| Sept. 28, 2011 |
|
Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals |
| Sept. 27, 2011 |
|
Merck Names Cuong Viet Do as Chief Strategy Officer |
| Sept. 23, 2011 |
|
Study of ZOLINZA® (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint |
| Sept. 20, 2011 |
|
Merck Joins Global Fight to Help Save Women's Lives During Pregnancy and Childbirth |
| Sept. 19, 2011 |
|
New Data on Odanacatib, Merck's Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research |
|
| Sept. 19, 2011 |
|
Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race |
|
| Sept. 14, 2011 |
|
Merck to Present at Bank of America Merrill Lynch Global Healthcare Conference |
| Sept. 13, 2011 |
|
Merck Partners with Susan G. Komen for the Cure® on Historic Initiative to Help Address Cervical and Breast Cancer in Developing Nations |
|
| Sept. 13, 2011 |
|
Merck and BGI Establish Strategic Collaboration Focused on Biomarkers and Genomic Technologies |
| Sept. 13, 2011 |
|
Merck Provides Update on the IMPROVE-IT Trial |
| Sept. 12, 2011 |
|
Merck to Present at Morgan Stanley Global Healthcare Conference |
| Sept. 7, 2011 |
|
Merck Statement on FOSAMAX® (alendronate sodium) Product Liability Trial |
|
| Aug. 26, 2011 |
|
Texas Supreme Court Finds for Merck in VIOXX® Case |
| Aug. 23, 2011 |
|
Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health |
| Aug. 18, 2011 |
|
Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus, Investigational mTOR Inhibitor |
| Aug. 3, 2011 |
|
Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV) |
| July 29, 2011 |
|
Merck Announces Second Quarter 2011 Financial Results |
| July 28, 2011 |
|
Merck Recognizes World Hepatitis Day With Partnerships and Grants to Support Global Hepatitis C Community |
| July 27, 2011 |
|
Latest Merck Manual Delivers Trusted Health Care Information in Print and Electronic Formats |
| July 26, 2011 |
|
Merck Announces Fourth Quarter 2011 Dividend |
| July 26, 2011 |
|
R&B Legend Natalie Cole Joins Rock Legend Gregg Allman, Merck and The American Liver Foundation to Turn Up the Volume Around Hep C |
| July 26, 2011 |
|
Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas |
| July 21, 2011 |
|
Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture |
| July 20, 2011 |
|
Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C |
|
| July 18, 2011 |
|
VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the European Union for Treatment of Chronic Hepatitis C |
|
| July 18, 2011 |
|
Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1 |
|
| July 11, 2011 |
|
Merck to Participate in New Research Efforts to Eradicate HIV |
July 1, 2011 |
|
Merck Receives Approval to Market GARDASIL®, ZOLINZA® and CUBICIN® in Japan |
|
| June 30, 2011 |
|
Merck to Hold Second-Quarter 2011 Sales and Earnings Conference Call on July 29 |
| June 29, 2011 |
|
Merck Announces New Name for its Animal Health Division |
| June 28, 2011 |
|
UPS and Merck Expand Their Distribution and Logistics Agreement |
June 25, 2011 |
|
In a New Post-Hoc Analysis Based on the AACE/ACE Diabetes Algorithm Significantly More Patients Achieved Blood Sugar Goals with Initial Therapy with Merck's Diabetes Medicine JANUMET® (sitagliptin/metformin HCl) Compared to Metformin Alone |
|
| June 21, 2011 |
|
Legendary Musician Gregg Allman Joins Merck and American Liver Foundation to Launch Tune In to Hep C Public Awareness Campaign |
| June 13, 2011 |
|
Merck and Hanwha Chemical Corporation Establish Global Strategic Collaboration to Develop and Commercialize Biosimilar Candidate |
| June 10, 2011 |
|
Merck Statement Regarding FDA Approval of Changes to Trade Packaging Design for Several Medicines from Merck |
| June 08, 2011 |
|
Actress JoAnna Garcia Swisher "Goes There" in a New Campaign with Merck to Motivate Women to "Get Real" When Talking to Their Physicians about Their Health |
| June 08, 2011 |
|
U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose -- 80 mg -- and Updated Drug Interaction Information |
|
| June 08, 2011 |
|
U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose -- 80 mg -- and Updated Drug Interaction Information |
|
| June 08, 2011 |
|
Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 |
| June 07, 2011 |
|
Merck to Present at Goldman Sachs 32nd Annual Healthcare Conference |
| June 07, 2011 |
|
Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies |
| June 06, 2011 |
|
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting |
| June 05, 2011 |
|
Merck Commends GAVI Alliance on Continued Efforts to Improve Access |
| June 02, 2011 |
|
Merck Signs on to United Nations CEO Water Mandate |
| May 31, 2011 |
|
Merck to Present at Sanford Bernstein 27th Strategic Decisions Conference |
| May 24, 2011 |
|
Merck Announces Third Quarter 2011 Dividend |
| May 20, 2011 |
|
CHMP Issues Positive Opinion for Merck's VICTRELIS™ (boceprevir), Oral Hepatitis C Virus (HCV) Protease Inhibitor |
|
| May 17, 2011 |
|
Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C |
| May 16, 2011 |
|
Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. |
| May 13, 2011 |
|
FDA Approves Merck's VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor |
|
| May 13, 2011 |
|
Merck Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. With Over 75 Percent of Shares Tendered |
| May 9, 2011 |
|
Merck Announces Hope Against Hepatitis C Initiative to Support Public Awareness, Education and Research in the Fight Against Hepatitis C Virus |
| May 2, 2011 |
|
Merck’s Investigational Prostaglandin Analogue Ophthalmic Medication Tafluprost Meets Primary Endpoint in Phase III Study |
| May 2, 2011 |
|
Merck to Present at Deutsche Bank 36th Annual Healthcare Conference |
| Apr. 29, 2011 |
|
Merck Announces First Quarter 2011 Financial Results |
| Apr. 28, 2011 |
|
Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire |
| Apr. 27, 2011 |
|
VICTRELIS™ (boceprevir) Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection |
| Apr. 27, 2011 |
|
Merck Announces New $5 Billion Share Repurchase Program |
| Apr. 25, 2011 |
|
Rwanda, Merck and QIAGEN Launch Africa's First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing |
|
| Apr. 21, 2011 |
|
Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases |
| Apr. 15, 2011 |
|
Merck Commences Tender Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc. |
| Apr. 15, 2011 |
|
Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI® |
| Apr. 15, 2011 |
|
Merck Reaffirms 2011 Non-GAAP EPS Target |
| Apr. 11, 2011 |
|
FDA Approves Merck's SYLATRON™ (peginterferon alfa-2b) for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement |
|
| Apr. 11, 2011 |
|
Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets |
| Apr. 11, 2011 |
|
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 |
| Apr. 06, 2011 |
|
U.S. Prescribing Information for GARDASIL® Updated; Indication Not Granted for Use in Adult Women |
|
| Apr. 05, 2011 |
|
Merck to Acquire Inspire Pharmaceuticals, Inc. |
| Apr. 01, 2011 |
|
Merck to Hold First-Quarter 2011 Sales and Earnings Conference Call on April 29 |
| Mar. 31, 2011 |
|
Jury Finds for Merck and Other Defendants on the Key Issue in an Environmental Contamination Lawsuit |
| Mar. 31, 2011 |
|
New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response |
| Mar. 31, 2011 |
|
VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control |
| Mar. 30, 2011 |
|
The New England Journal of Medicine (NEJM) Publishes Pivotal Studies Showing Merck's Investigational Medicine VICTRELIS™ (boceprevir) in Combination Therapy Significantly Increased SVR In Patients with Chronic HCV Genotype 1 Who Failed Previous Treatment or Who Were New to Treatment Compared to Control |
| Mar. 25, 2011 |
|
FDA Expands Indication for ZOSTAVAX®, Merck's Shingles Vaccine,to Include Adults Ages 50 to 59 |
|
| Mar. 24, 2011 |
|
Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck |
| Mar. 22, 2011 |
|
Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health |
| Mar. 16, 2011 |
|
Merck Receives 2011 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA) |
| Mar. 15, 2011 |
|
Merck to Present at Barclays Capital 2011 Global Healthcare Conference |
| Mar. 10, 2011 |
|
SisterLove, Inc. and Merck Launch "Everyone Has A Story" Series |
| Mar. 09, 2011 |
|
Merck Announces FDA Acceptance of New Drug Application for Investigational Ophthalmic Medication SAFLUTAN® (tafluprost) |
| Mar. 07, 2011 |
|
Merck Announces New Data Analyses for VICTRELIS™ (Boceprevir) will be Presented at The International Liver Congress™ / 2011 EASL Annual Meeting |
| Mar. 07, 2011 |
|
Merck to Present at Cowen and Company's 31st Annual Health Care Conference |
| Mar. 01, 2011 |
|
Merck's ISENTRESS® (raltegravir) Demonstrated Durable Reductions in HIV-1 Viral Load and Sustained Tolerability At Three Years of Treatment in Previously Untreated Adult Patients Infected with HIV-1 |
|
| Feb. 28, 2011 |
|
Merck to Present at Citi 2011 Global Health Care Conference |
| Feb. 28, 2011 |
|
Fujifilm to Acquire Merck Biomanufacturing Network |
| Feb. 22, 2011 |
|
Merck Announces Second Quarter 2011 Dividend |
| Feb. 14, 2011 |
|
Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial |
|
| Feb. 03, 2011 |
|
Merck Announces Fourth Quarter and Full Year 2010 Financial Results |
| Feb. 02, 2011 |
|
New England Journal of Medicine Publishes Efficacy and Safety Data for GARDASIL® in Males |
|
| Jan. 25, 2011 |
|
John J. Horan, Former Merck Chairman and CEO Dies of Natural Causes at 90 Years of Age |
| Jan. 18, 2011 |
|
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey State Court |
|
| Jan. 12, 2011 |
|
Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates |
| Jan. 11, 2011 |
|
Merck to Present at the 29th Annual J.P. Morgan Healthcare Conference |
| Jan. 04, 2011 |
|
Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3 |
| Dec. 07, 2010 |
|
Merck Prices $2.0 Billion Debt Offering |
| Dec. 02, 2010 |
|
Merck to Acquire SmartCells, Inc. |
| Nov. 30, 2010 |
|
Merck Board Elects Kenneth C. Frazier as Next CEO; Richard T. Clark to Continue as Chairman |
| Nov. 23, 2010 |
|
Merck Announces First-Quarter 2011 Dividend |
| Nov. 19, 2010 |
|
Merck Wins Another Federal FOSAMAX® (alendronate sodium) Bellwether Trial |
|
| Nov. 11, 2010 |
|
Merck and Partners Make Progress In Long-Term Commitment To End River Blindness |
| Oct. 29, 2010 |
|
Merck Announces Third-Quarter 2010 Financial Results |
| Oct. 28, 2010 |
|
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court |
|
| Oct. 13, 2010 |
|
Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach |
| Oct. 13, 2010 |
|
Tenth Edition of The Merck Veterinary Manual Debuts |
| Oct. 12, 2010 |
|
Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Markets Outside of the United States, China and Japan |
|
| Oct. 04, 2010 |
|
Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX® (alendronate sodium) Case |
|
| Oct. 01, 2010 |
|
Merck to Hold Third-Quarter 2010 Sales and Earnings Conference Call on Oct. 29 |
| Sept. 30, 2010 |
|
Merck to Appeal Verdict in Massachusetts Medicaid Case |
| Sept. 29, 2010 |
|
Why So Shy? What Females of the Facebook Generation Are Not Sharing in the OB/GYN Office that Could Affect Their Health |
| Sept. 22, 2010 |
|
Merck Significantly Expands its Patient Assistance Program Offerings to Provide Access to More Medicines for People in Need |
| Sept. 16, 2010 |
|
Merck's Non-Profit to Advance Science Education Joins President Obama's Educate to Innovate Campaign |
| Aug. 24, 2010 |
|
Merck Provides New Funding to Fight HIV/AIDS in Botswana |
| Aug. 12, 2010 |
|
Merck Announces Mandatory Conversion of its 6.00% Mandatory Convertible Preferred Stock |
| Aug. 10, 2010 |
|
Merck Partners With Sesame Workshop on National Program to Encourage Healthy Eating Habits in Families with a Limited Budget |
| Aug. 10, 2010 |
|
Black AIDS Institute, in Partnership with Merck, Launches Dynamic National HIV/AIDS Treatment and Care Advocacy Network |
| Jul. 30, 2010 |
|
Merck Announces Second-Quarter 2010 Financial Results |
| Jul. 27, 2010 |
|
Merck Grants License to LabCorp for Development of Test To Potentially Identify Patients Likely to Respond to Hepatitis C Therapy |
| Jul. 27, 2010 |
|
Merck Announces Fourth-Quarter 2010 Dividend |
| Jul. 27, 2010 |
|
Sanofi-aventis and Merck Appoint Raul Kohan as CEO for the New Animal Health Joint Venture |
| Jul. 27, 2010 |
|
Sinopharm and Merck Sign Statement of Mutual Intent |
| Jul. 08, 2010 |
|
Merck Details Plans to Advance Integration of R&D, Manufacturing and Business Operations Worldwide |
| Jun. 30, 2010 |
|
Merck to Hold Second-Quarter 2010 Sales and Earnings Conference Call on July 30 |
| Jun. 29, 2010 |
|
Merck Wins Case Filed by Louisiana Attorney General Involving VIOXX® |
| Jun. 25, 2010 |
|
Merck Challenges Verdict in Federal FOSAMAX® (alendronate sodium) Trial |
|
| Jun. 24, 2010 |
|
Merck to Expand Business in South Africa |
| Jun. 21, 2010 |
|
UNCF/MERCK Science Initiative Awards Scholarships and Fellowships to African American in Bioscience |
| Jun. 07, 2010 |
|
Statement on FOSAMAX® (alendronate sodium)
Product Liability Trial in U.S. District Court |
|
| May 26, 2010 |
|
Merck Announces Third Quarter 2010 Dividends |
| May 11, 2010 |
|
Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy for Growth in Emerging Markets |
| May 11, 2010 |
|
Merck Highlights Robust Late-Stage Pipeline, Global Business Strategy and Progress of Integration |
| May 05, 2010 |
|
Merck Wins Second Federal FOSAMAX® (alendronate sodium) Bellwether Trial |
| May 05, 2010 |
|
Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation Partner on Vaccination Program with GARDASIL® for Girls and Young Women of Bhutan |
|
| May 04, 2010 |
|
Merck Announces First-Quarter 2010 Financial Results |
| Apr. 28, 2010 |
|
Merck Announces Senior Management Appointments |
| Apr. 27, 2010 |
|
U.S. Supreme Court Affirms Lower Court Decision on Merck Federal Securities Class Action |
| Apr. 26, 2010 |
|
Nycomed and Merck & Co., Inc., Announce Commercialization Agreements For Daxas® in Europe and Canada |
| Apr. 23, 2010 |
|
Merck Provides Information on Impact of U.S. Health Care Reform Legislation |
| Apr. 21, 2010 |
|
Merck Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus-Diphtheria (Td) Vaccine in the U.S. |
|
| Apr. 19, 2010 |
|
Merck Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court |
|
| Apr. 12, 2010 |
|
Statement on Vioxx® Consumer Product Trial in U.S. District Court for the Eastern District of Louisiana. |
| Apr. 07, 2010 |
|
Merck to Hold First-Quarter 2010 Sales and Earnings Conference Call on May 4 |
| Mar. 09, 2010 |
|
Sanofi-aventis and Merck to create a Global Leader in Animal Health |
| Mar. 09, 2010 |
|
Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw |
|
| Mar. 04, 2010 |
|
Merck Statement on Vioxx® Judgment in Australia |
| Mar. 02, 2010 |
|
Merck Receives 2010 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA) |
| Mar. 01, 2010 |
|
AstraZeneca Exercises Option to Acquire Merck's Interest in Partnership Products |
| Feb. 23, 2010 |
|
Merck Announces Second Quarter 2010 Dividends |
| Feb. 16, 2010 |
|
Merck Announces Fourth-Quarter and Full-Year 2009 Financial Results |
| Feb. 15, 2010 |
|
Merck Appoints Bridgette P. Heller As Executive Vice President and Preside nt, Consumer Health Care |
The information contained in each news release posted on this page was factually accurate on the date it was issued. The company assumes no duty to update the information to reflect subsequent developments. Readers of the news releases should not rely upon the information as current or accurate after their issuance dates.
